Proqr Thrapeutics N V (PRQR) Shareholder Kerrisdale Advisers LLC Boosted Position
Posted by Carillo Anthony on November 26, 2019 at 2:49 pm
ProQR Therapeutics N.V. (NASDAQ:PRQR) Logo
Kerrisdale Advisers Llc increased its stake in Proqr Thrapeutics N V (PRQR) by 631.12% based on its latest 2019Q2 regulatory filing with the SEC. Kerrisdale Advisers Llc bought 401,900 shares as the company’s stock declined 20.18% . The hedge fund held 465,580 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $4.24 million, up from 63,680 at the end of the previous reported quarter. Kerrisdale Advisers Llc who had been investing in Proqr Thrapeutics N V for a number of months, seems to be bullish on the $322.20M market cap company. The stock increased 0.36% or $0.03 during the last trading session, reaching $8.28. About 8,328 shares traded. ProQR Therapeutics N.V. (NASDAQ:PRQR) has risen 32.03% since November 26, 2018 and is uptrending. It has outperformed by 32.03% the S&P500.
More notable recent ProQR Therapeutics N.V. (NASDAQ:PRQR) news were published by: Finance.Yahoo.com which released: “Is Exantas Capital Corp. (XAN) A Good Stock To Buy? – Yahoo Finance” on November 07, 2019, also Globenewswire.com with their article: “ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 – GlobeNewswire” published on April 15, 2019, Globenewswire.com published: “ProQR to Present at the RBC Capital Markets Healthcare Conference – GlobeNewswire” on May 15, 2019. More interesting news about ProQR Therapeutics N.V. (NASDAQ:PRQR) were released by: Seekingalpha.com and their article: “ProQR Therapeutics on watch after FDA win – Seeking Alpha” published on November 21, 2019 as well as Nasdaq.com‘s news article titled: “Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates – Nasdaq” with publication date: November 05, 2019.
ProQR Therapeutics N.V. (NASDAQ:PRQR) Ratings Coverage
Among 2 analysts covering ProQR (NASDAQ:PRQR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ProQR has $3300 highest and $25 lowest target. $29’s average target is 250.24% above currents $8.28 stock price. ProQR had 2 analyst reports since October 11, 2019 according to SRatingsIntel. The rating was maintained by Citigroup with “Buy” on Tuesday, November 19. The firm has “Buy” rating given on Friday, October 11 by Chardan Capital Markets.